Latest News for RO.SW
FDA approval is based on results from the landmark phase III ATOMIC study, published in The New England Journal of Medicine, which showed Tecentriq plus chemotherapy reduced the risk of disease recurrence or death by 50% compared to chemotherapy alone1First approved adjuvant immunotherapy regimen for stage III dMMR colon cancer, positioning Tecentriq as a new post-surgery standard of care Nearly 25% of all colon…
In the phase III IMAgINATION study, sefaxersen demonstrated statistically significant and clinically meaningful reductions in proteinuria versus placebo at 37 weeks, showing best-in-class potentialSefaxersen inhibits complement factor B production at its primary source in the liver, thus blocking a key driver of IgAN-related kidney damage1IgAN is a progressive kidney disease that is typically diagnosed in young…
/PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received FDA approval for expanded use of its PATHWAY HER2 (4B5) and VENTANA
/PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its cobas
Konzernverkäufe stiegen in den ersten sechs Monaten um6% zu konstanten Wechselkursen (CER1; in CHF ausgewiesen -2% und auf USD-Basis28%) aufgrund hoher Nachfrage nach innovativen Medikamenten und Diagnostika. Verkäufe der Division Pharma erhöhten sich um6% (CER; in CHF ausgewiesen -1% und auf USD-Basis8%) aufgrund des kontinuierlich hohen Umsatzwachstums unserer Medikamente in allen Therapiebereichen; die…
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for RO.SW.
Senate Trading
No Senate trades found for RO.SW.
U.S. House Trading
No House trades found for RO.SW.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.